Tianjin Lisheng Pharmaceutical Co.,Ltd. (SHE:002393)

Market Cap	6.06B +39.1%
Revenue (ttm)	1.39B +4.2%
Net Income	418.37M +126.7%
EPS	1.62 +125.0%
Shares Out	256.89M
PE Ratio	14.56
Forward PE	n/a
Dividend	0.35 (1.46%)
Ex-Dividend Date	Feb 11, 2026

Volume	5,191,923
Average Volume	7,161,991
Open	23.77
Previous Close	23.90
Day's Range	23.48 - 24.36
52-Week Range	14.90 - 28.77
Beta	0.13
RSI	58.40
Earnings Date	Mar 25, 2026

About SHE:002393

Tianjin Lisheng Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of pharmaceutical products in China and internationally. The company offers its products in various forms comprising tablets, capsules, granules, and injections for use in various therapeutic fields, such as nervous system, musculoskeletal, genitourinary system, antineoplastic and immune system, sensory system, systemic anti-infection, respiratory system, endocrine system, digestive system, and cardiovascular system, as well as drugs for invigo...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1951
• Employees: 1,604
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 002393

Financial Performance

In 2025, SHE:002393's revenue was 1.39 billion, an increase of 4.23% compared to the previous year's 1.34 billion. Earnings were 418.37 million, an increase of 126.72%.